185-72-8

Usage

Uses

Used in Chemical Industry:
1,6-Dioxaspiro[2.5]octane is used as a solvent in the production of cellulose acetate, which is a key component in the manufacturing of photographic film and other cellulose-based products.
Used in Paint and Coatings Industry:
1,6-Dioxaspiro[2.5]octane is used as a solvent in the formulation of lacquers, varnishes, and paint strippers, providing a means to dissolve and remove paint and other coatings effectively.
Used in Pharmaceutical Industry:
1,6-Dioxaspiro[2.5]octane is utilized as a solvent for pharmaceuticals, aiding in the dissolution and delivery of active ingredients in various medicinal formulations.
Used in Stabilization of Chlorinated Solvents:
1,6-Dioxaspiro[2.5]octane serves as a stabilizer for chlorinated solvents, preventing the formation of harmful byproducts and extending the shelf life of these solvents.
Used in Resin Industry:
1,6-Dioxaspiro[2.5]octane is employed as a solvent in the production of resins, contributing to the manufacturing process of various plastic materials and adhesives.
It is crucial to note that due to its hazardous nature, 1,6-Dioxaspiro[2.5]octane can contaminate groundwater and pose health risks through inhalation exposure, potentially affecting the central nervous system, liver, and kidneys. Therefore, proper handling, use, and disposal are essential to mitigate its impact on human health and the environment.

InChI:InChI=1/C6H10O2/c1-3-7-4-2-6(1)5-8-6/h1-5H2

Upstream product

• 186581-53-3 diazomethane 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 67-56-1 methanol 
• 60-29-7 diethyl ether 
• 36838-71-8 4-methylene-tetrahydro-pyran 
• 5034-06-0 trimethyl sulfoxonium chloride 
• 2081-44-9 Tetrahydro-pyran-4-ol 
• 1774-47-6 trimethylsulfoxonium iodide 
• 2181-42-2 trimethylsulphonium iodide 
• 1030268-24-6 trimethylsulphoxonium iodide 

Downstream Products

• 50675-18-8 3,4,5,6-tetrahydro-2H-pyran-4-carbaldehyde 
• 136561-23-4 2-Acetylamino-3-phenyl-propionic acid 4-hydroxy-tetrahydro-pyran-4-ylmethyl ester 
• 136561-21-2 3-Phenyl-2-(toluene-4-sulfonylamino)-propionic acid 4-hydroxy-tetrahydro-pyran-4-ylmethyl ester 
• 136561-22-3 2-Benzoylamino-3-methyl-butyric acid 4-hydroxy-tetrahydro-pyran-4-ylmethyl ester 
• 783303-73-1 4-(aminomethyl)tetrahydro-2H-pyran-4-ol 
• 944953-43-9 4-[(3S,4R,5R)-4-(4-methoxyphenyl)-5-[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethoxy]-1-(toluene-4-sulfonyl)piperidin-3-yloxymethyl]tetrahydropyran-4-ol 
• 1046788-31-1 4-(((2R,5S)-4-benzyl-2,5-dimethylpiperazin-1-yl)methyl)tetrahydro-2H-pyran-4-ol 
• 1210226-44-0 6-methylbenzo[b]thiophene-2-carboxylic acid [1-(2-phenyl-1(R)-{[1-(4-hydroxytetrahydropyran-4-ylmethyl)piperidin-4-ylmethyl]carbamoyl}ethylcarbamoyl)cyclopentyl]amide 
• 1010836-50-6 (4-methoxytetrahydro-2H-pyran-4-yl)methanol 
• 1263374-29-3 toluene-4-sulfonic acid 4-methoxy-tetrahydro-pyran-4-yl methyl ester 
• 1613301-32-8 [(S)-6-((R)-7-fluoro-4-{3-fluoro-4-[(4-hydroxytetrahydro-2H-pyran-4-yl)methoxy]phenoxy}indan-1-yloxy)-2,3-dihydrobenzofuran-3-yl]acetic acid methyl ester 

Relevant academic research and scientific papers

Design of iodinated radioligands for SPECT imaging of central human 5-HT4R using a ligand lipophilicity efficiency approach

A series of iodinated ligands for the SPECT imaging of 5-HT4 receptors was designed starting from the previously reported hit MR-26132. We focused on the modulation of the piperidine-containing lateral chain by introducing hydrophilic groups in order to decrease the liphophilicity of the new ligands. All the synthesized compounds were tested for their binding affinities on 5-HT4Rs and based on the Ligand Lipophilicity Efficiency approach, compound 13 was further selected for radioiodination with iodine-125 and imaging experiments. Compound 13 showed its ability to displace the specific signal of the reference compound [125I]SB-207710 but no significant detection of [125I]13 was observed in vivo in SPECT experiments.

NON-FUSED TRICYCLIC COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

AMINO-QUINOLINES AS KINASE INHIBITORS

Disclosed are compounds having the formula:wherein R 1 , R 2 , R 3 and Z are as defined herein, and methods of making and using the same.

OXYSTEROLS AND METHODS OF USE THEREOF

Compounds are provided according to Formula (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein A, R1, and R5 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

ANTI-BACTERIAL COMPOUNDS

A compound of Formula (II): for use in the prevention or treatment of a bacterial infection.

AMINO-QUINOLINES AS KINASE INHIBITORS

Disclosed are compounds having the formula: wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.

AMINO-QUINOLINES AS KINASE INHIBITORS

Disclosed are compounds having the formula: wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.

TRIAZOLYL DERIVATIVES AS SYK INHIBITORS

Provided are triazole derivatives of Formula I which are potent inhibitors of spleen tyrosine kinase and pharmaceutical composition. The triazole derivatives are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

FURO[3,4-C]QUINOLINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION

The present invention relates to compounds defined by formula (I), wherein the variables R1-R8 are defined as in the description, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of cholesterol

Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation

The present invention relates to compounds defined by formula I wherein the variables R1-R8 are defined as in the description, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of cholesterol es